US eligibility and preventable cardiovascular disease events from semaglutide in type 2 diabetes
Background The SUSTAIN-6 trial showed the cardiovascular disease (CVD) benefits of semaglutide among patients with type 2 diabetes mellitus (T2DM). We estimated the US population eligibility and preventable CVD events from semaglutide. Methods US adults with T2DM were selected from the National Heal...
محفوظ في:
| المؤلفون الرئيسيون: | , , |
|---|---|
| التنسيق: | Artigo |
| اللغة: | Inglês |
| منشور في: |
SAGE Publishing
2025-09-01
|
| سلاسل: | Diabetes & Vascular Disease Research |
| الوصول للمادة أونلاين: | https://doi.org/10.1177/14791641251376551 |
| الوسوم: |
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!
|